{
    "nctId": "NCT05514054",
    "briefTitle": "A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer",
    "officialTitle": "EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 6000,
    "primaryOutcomeMeasure": "Invasive Disease-Free Survival (IDFS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Have a diagnosis of ER+, HER2- early-stage, resected, invasive breast cancer without evidence of distant metastasis.\n* Participants must have received at least 24 months but not more than 60 months of any adjuvant ET, from time of adjuvant ET initiation.\n* Participants may have received (neo) adjuvant chemotherapy and/or targeted therapy with a CDK4/6- or PARP- inhibitor.\n* Must have an increased risk of disease recurrence based on clinical-pathological risk features.\n* Have a Performance Status of 0 or 1 on the Eastern Cooperative Oncology Group scale.\n* Have adequate organ function.\n\nExclusion Criteria:\n\n* Have any evidence of metastatic disease (including contralateral ALN) or inflammatory breast cancer at primary breast cancer diagnosis.\n* Participants with more than a 6-month consecutive gap in therapy during the course of prior adjuvant ET.\n* Participants who have completed or discontinued prior adjuvant ET \\>6 months prior to screening.\n* Participants with a history of previous breast cancer are excluded, with the exception of ipsilateral DCIS treated by locoregional therapy alone \u22655 years ago.\n* Pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 180 days after the last dose of study intervention.\n* Participant has previously received ET of any duration for breast cancer prevention (tamoxifen or AIs) or raloxifene.\n* Participants with a history of any other cancer.\n* Have serious preexisting medical conditions that, in the judgment of the investigator, would preclude participation in this study.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}